Nucleic Acid Vaccine Formulation for Ambient-Stable SARS-CoV-2 Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for a safe and effective vaccine and treatment for SARS-CoV-2 infections, particularly for the elderly population, as no specific treatment is currently available, and existing vaccines are costly, require cold storage, and are not suitable for rapid production.
Innovation Solution
A nucleic acid-based vaccine comprising coding sequences for SARS-CoV-2 antigens, which can be administered without cold storage and induces strong immune responses, including CD8+ and CD4+ T-cell responses, humoral immunity, and mucosal IgA immunity, with potential for one to two doses for sufficient protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines are used, then immune protection is achieved, but cold storage is required and production cost increases
Solution Approach 1:
The patent changes the physical-chemical parameters of the vaccine formulation by incorporating specific adjuvants and stabilizing agents that allow the vaccine to maintain stability and efficacy at ambient temperatures. This parameter modification eliminates the need for cold chain storage while preserving immune protection capabilities.
Solution Approach 2:
The patent introduces intermediary substances such as stabilizing agents and adjuvants that mediate between the vaccine antigen and the immune system. These intermediaries enhance the vaccine's stability at higher temperatures while maintaining its ability to induce protective immune responses.
2Reliability
If conventional vaccines are used, then immune protection is achieved, but production cost increases and rapid production becomes difficult
Solution Approach 1:
The patent segments the vaccine development process into modular components, including separate antigen production units and adjuvant formulations. This segmentation enables parallel processing and independent optimization of each component, significantly accelerating production speed while maintaining vaccine efficacy.
Solution Approach 2:
The patent modifies production parameters such as cultivation conditions, formulation methods, and quality control thresholds to enable rapid-scale production. These parameter changes allow for faster manufacturing cycles without compromising the immune protection the vaccine provides.
3Reliability
If conventional vaccines are used, then immune protection is achieved, but cost becomes a barrier for widespread distribution
Solution Approach 1:
The patent employs cost-effective, easily synthesizable adjuvants and stabilizing agents that can be produced at low cost through standardized manufacturing processes. These inexpensive components enable mass production and distribution while maintaining the vaccine's ability to provide reliable immune protection.
Solution Approach 2:
The patent optimizes formulation parameters to reduce material costs and simplify manufacturing procedures. By adjusting concentrations, selecting cheaper but effective excipients, and streamlining the production process, the patent achieves cost reduction without sacrificing the immune protection efficacy.
Data Source
AI summary
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.